RU2020110573A3 - - Google Patents

Download PDF

Info

Publication number
RU2020110573A3
RU2020110573A3 RU2020110573A RU2020110573A RU2020110573A3 RU 2020110573 A3 RU2020110573 A3 RU 2020110573A3 RU 2020110573 A RU2020110573 A RU 2020110573A RU 2020110573 A RU2020110573 A RU 2020110573A RU 2020110573 A3 RU2020110573 A3 RU 2020110573A3
Authority
RU
Russia
Application number
RU2020110573A
Other versions
RU2020110573A (ru
RU2797518C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2020110573A publication Critical patent/RU2020110573A/ru
Publication of RU2020110573A3 publication Critical patent/RU2020110573A3/ru
Application granted granted Critical
Publication of RU2797518C2 publication Critical patent/RU2797518C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
RU2020110573A 2017-08-15 2018-08-15 Модуляторы пируваткиназы и их применение RU2797518C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/097496 2017-08-15
CN2017097496 2017-08-15
US201862673533P 2018-05-18 2018-05-18
US201862673526P 2018-05-18 2018-05-18
US62/673,526 2018-05-18
US62/673,533 2018-05-18
PCT/US2018/000129 WO2019035865A1 (en) 2017-08-15 2018-08-15 MODULATORS OF PYRUVATE KINASE AND THEIR USE

Publications (3)

Publication Number Publication Date
RU2020110573A RU2020110573A (ru) 2021-09-16
RU2020110573A3 true RU2020110573A3 (ru) 2021-12-24
RU2797518C2 RU2797518C2 (ru) 2023-06-06

Family

ID=

Also Published As

Publication number Publication date
MX2020001833A (es) 2020-07-22
UA126292C2 (uk) 2022-09-14
IL292530A (en) 2022-06-01
WO2019035864A1 (en) 2019-02-21
MX2020001832A (es) 2020-07-22
ES2944545T3 (es) 2023-06-22
RU2020110573A (ru) 2021-09-16
US20220233541A1 (en) 2022-07-28
EP3668512A1 (en) 2020-06-24
PE20200724A1 (es) 2020-07-21
US11464775B2 (en) 2022-10-11
PL3668512T3 (pl) 2023-06-19
WO2019035863A8 (en) 2019-03-28
JP2023052478A (ja) 2023-04-11
ES2905100T3 (es) 2022-04-07
EP3668512B1 (en) 2023-02-15
IL272599A (en) 2020-03-31
US11872225B2 (en) 2024-01-16
TW201919631A (zh) 2019-06-01
WO2019035864A8 (en) 2019-03-28
CR20200123A (es) 2020-06-29
PT3668512T (pt) 2023-05-22
WO2019035865A8 (en) 2019-03-28
JP2023027276A (ja) 2023-03-01
SI3668512T1 (sl) 2023-06-30
RS64221B1 (sr) 2023-06-30
US11040036B2 (en) 2021-06-22
IL292530B2 (en) 2023-06-01
TW201920203A (zh) 2019-06-01
IL272599B (en) 2022-08-01
CA3072455A1 (en) 2019-02-21
FI3668512T3 (fi) 2023-05-12
ES2966825T3 (es) 2024-04-24
RS62871B1 (sr) 2022-02-28
KR20230127364A (ko) 2023-08-31
US20200206225A1 (en) 2020-07-02
DK3668513T3 (da) 2022-01-10
PH12020500343A1 (en) 2021-02-08
CO2020002961A2 (es) 2020-04-13
EP4026838A1 (en) 2022-07-13
SG11202001353PA (en) 2020-03-30
TWI796353B (zh) 2023-03-21
IL272597B (en) 2022-06-01
US20210130371A1 (en) 2021-05-06
LT3668513T (lt) 2022-03-25
AU2018316588B2 (en) 2023-02-02
US11957680B2 (en) 2024-04-16
CN111032045A (zh) 2020-04-17
JP2020531432A (ja) 2020-11-05
ECSP20018487A (es) 2020-05-29
TW202323258A (zh) 2023-06-16
CN117186119A (zh) 2023-12-08
BR112020003254A2 (pt) 2020-10-27
EP3668513B1 (en) 2021-11-10
EP3668513A1 (en) 2020-06-24
US11364240B2 (en) 2022-06-21
SG11202001262QA (en) 2020-03-30
AU2018316587B2 (en) 2023-05-11
JP7301040B2 (ja) 2023-06-30
BR112020003262A2 (pt) 2020-09-01
KR20200054200A (ko) 2020-05-19
US20200207785A1 (en) 2020-07-02
CA3071993A1 (en) 2019-02-21
HRP20230452T1 (hr) 2023-07-21
CN111032045B (zh) 2023-08-15
HUE061910T2 (hu) 2023-08-28
JP7275107B2 (ja) 2023-05-17
IL272597A (en) 2020-03-31
DK3668512T3 (da) 2023-05-22
EP3668881A1 (en) 2020-06-24
PL3668513T3 (pl) 2022-03-21
CN111032046A (zh) 2020-04-17
AU2023202772A1 (en) 2023-05-18
KR102642408B1 (ko) 2024-02-28
CN111032046B (zh) 2023-09-26
PT3668513T (pt) 2022-01-21
TWI823580B (zh) 2023-11-21
CL2020000375A1 (es) 2020-12-11
US20210077490A1 (en) 2021-03-18
HUE057178T2 (hu) 2022-04-28
JP2020531443A (ja) 2020-11-05
AU2018316588A1 (en) 2020-02-20
KR20200054199A (ko) 2020-05-19
US20220395503A1 (en) 2022-12-15
CY1124953T1 (el) 2023-01-05
MD3668513T2 (ro) 2022-04-30
TWI790271B (zh) 2023-01-21
WO2019035863A1 (en) 2019-02-21
US11590132B2 (en) 2023-02-28
EP3668881B1 (en) 2023-10-04
HRP20220039T1 (hr) 2022-04-15
AU2018316587A1 (en) 2020-02-20
CO2020002959A2 (es) 2020-04-13
WO2019035865A1 (en) 2019-02-21
LT3668512T (lt) 2023-06-12
US20230226055A1 (en) 2023-07-20
SI3668513T1 (sl) 2022-04-29

Similar Documents

Publication Publication Date Title
BR122021024397A2 (ru)
BR122021023687A2 (ru)
BR122022003522A2 (ru)
BR122021000189A2 (ru)
BR112019008823A2 (ru)
BR112020006084A8 (ru)
BR122021014832A2 (ru)
RU2020110573A3 (ru)
BR112020008820A2 (ru)
BR102017023327A2 (ru)
BE2017C035I2 (ru)
BR102017015495A2 (ru)
BR102017015250A2 (ru)
BR102017014430A2 (ru)
BR202017010373U2 (ru)
BR202017009870U2 (ru)
BR202017006953U2 (ru)
BR202017004898U2 (ru)
BR102017003115A2 (ru)
BR202017002937U2 (ru)
BR202017002826U2 (ru)
CN304060551S (ru)
CN303990998S (ru)
CN304110475S (ru)
CN304109920S (ru)